SCHEMBL14488692

SCHEMBL14488692

CC1CCN(c2ccc(C(C)C)cc2)C1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.49
LIPE Q05469 1/20 0.45
MGLL Q99685 1/20 0.43
MCOLN3 Q8TDD5 1/20 0.42
PIK3CD O00329 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CCNA2 P20248 2/20 0.37
CDK2 P24941 2/20 0.37
CCNA1 P78396 2/20 0.37
TDP1 Q9NUW8 1/20 0.36
GRM2 Q14416 1/20 0.36
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8299294 0.84 LIPE (0.38) L3MBTL1LIPEPIK3CDCCNA2CDK2
SCHEMBL6783378 0.83 LMNA (0.50) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL25269677 0.83 HDAC6 (0.46) KMT2AMEN1MAPTHPGD
SCHEMBL14488688 0.82 L3MBTL1 (0.44) L3MBTL1LIPEMGLLMCOLN3KMT2A
SCHEMBL12528001 0.81 HTT (0.48) KMT2AMEN1MAPTHPGDNPC1
SCHEMBL25868401 0.79 ROCK2 (0.50) MGLLKMT2AMEN1MAPTRAB9A
SCHEMBL12015718 0.79 MEN1 (0.50) L3MBTL1KMT2AMEN1MAPTHPGD
SCHEMBL266004 0.79 MEN1 (0.50) L3MBTL1KMT2AMEN1MAPTHPGD
SCHEMBL892627 0.78 PTPN1 (0.55) L3MBTL1LIPEMGLLKMT2AMEN1
SCHEMBL19327276 0.77 ROCK2 (0.48) MGLLKMT2AMEN1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7235544-B2 for use in conjunction with thrombolytic agents, thus permitting the use of a lower dose of thrombolytic agent; treatment of acute vascular diseases; may have potential in neurogenerative diseases such as Parkinson's and Alzheimer's disease GLAXO GROUP LIMITED (GB) 2007-06-26 US disclosed